Gilead Sciences Debt/Equity Ratio 2010-2024 | GILD

Gilead Sciences debt/equity ratio for the quarter ending September 30, 2024 was 1.24.

  • Gilead Sciences average debt/equity ratio for 2023 was 1.08, a 11.48% increase from 2022.
  • Gilead Sciences average debt/equity ratio for 2022 was 1.22, a 10.29% decline from 2021.
  • Gilead Sciences average debt/equity ratio for 2021 was 1.36, a 1.45% decline from 2020.

Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.

Gilead Sciences Debt/Equity Ratio 2010-2024 | GILD

  • Gilead Sciences average debt/equity ratio for 2023 was 1.08, a 11.48% increase from 2022.
  • Gilead Sciences average debt/equity ratio for 2022 was 1.22, a 10.29% decline from 2021.
  • Gilead Sciences average debt/equity ratio for 2021 was 1.36, a 1.45% decline from 2020.

Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$158.3B
Bristol Myers Squibb (BMY)$119.4B
Vertex Pharmaceuticals (VRTX)$116.1B
CSL (CSLLY)$87.2B
Regeneron Pharmaceuticals (REGN)$81.1B
GSK (GSK)$70.4B
Argenex SE (ARGX)$36.2B
Alnylam Pharmaceuticals (ALNY)$31.6B
BioNTech SE (BNTX)$27.1B
Biogen (BIIB)$23B
Illumina (ILMN)$22.2B
BeiGene (BGNE)$18.6B
Moderna (MRNA)$15.8B
Incyte (INCY)$13.8B
Genmab (GMAB)$13.7B
Insmed (INSM)$13.1B
BioMarin Pharmaceutical (BMRN)$12.2B
Bio-Techne Corp (TECH)$11.3B
Vaxcyte (PCVX)$11B
Sarepta Therapeutics (SRPT)$10.9B
Exelixis (EXEL)$10.2B
Exact Sciences (EXAS)$9.8B
QIAGEN (QGEN)$9.8B
Revolution Medicines (RVMD)$9.5B
Bio-Rad Laboratories (BIO.B)$9.4B
Roivant Sciences (ROIV)$9.3B
Intra-Cellular Therapies (ITCI)$9.1B
Repligen (RGEN)$8B
Ascendis Pharma (ASND)$7.9B
Legend Biotech (LEGN)$7.5B